Disruption of ATP binding in HER3 by mutation has previously been shown to inhibit its signaling (Claus et al., 2018), and we further demonstrate that this requirement cannot be overcome by massive HER2 overexpression as seen in HER2-amplified cancers. The gene discussed is ERBB3; the disease is cancer.